Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug

Chan, Lilia; Asriel, Benjamina; Eaton, Ellen, F.b; Wyatt, Christina, M.a

Current Opinion in Nephrology and Hypertension: March 2018 - Volume 27 - Issue 2 - p 102–112
doi: 10.1097/MNH.0000000000000392
CLINICAL NEPHROLOGY: Edited by Bertrand L. Jaber
Buy

Purpose of review The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations. Although TDF is well tolerated, the potential for kidney and bone toxicity has important implications for public health given the large number of individuals exposed to TDF worldwide. This review summarizes the recent literature on kidney and bone health in individuals treated with TDF and the newer prodrug tenofovir alafenamide (TAF).

Recent findings Risk factors for TDF toxicity appear to be similar in patients treated for HIV or hepatitis B virus and in HIV-uninfected PrEP users, although drug–drug interactions are a more important concern in HIV-positive individuals. The risk of toxicity appears to be lower with TAF, but further studies are needed to confirm the safety of long-term use and to evaluate the efficacy of TAF-based PrEP.

Summary Nephrologists should be aware of the potential kidney and bone toxicity of TDF, as well as unique situations in which the newer prodrug TAF may contribute to kidney injury.

aDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York

bDivision of Infectious Diseases, Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama, USA

Correspondence to Christina M. Wyatt, MD, MSc, Associate Professor of Medicine, Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1243, New York, NY 10029, USA. Tel: +1 212 241 8004; fax: +1 212 987 0389; e-mail: Christina.wyatt@mssm.edu

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.